Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia

Chabrol, Amélie; Huguet, Françoise; Alvarez, Muriel; Verdeil, X.; Linas, Marie Denise; Cassaing, Sophie; Giron, J.; Têtu, L.; Attal, Michel; Récher, Christian

doi:10.3324/haematol.2009.012633

Cited by 36 publications

(34 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, we have previously reported that 50% of AML patients with invasive aspergillosis had an adverse prognosis according to their cytogenetic features and most patients who died of invasive aspergillosis‐related complications were refractory to chemotherapy. Furthermore, patients with low‐risk cytogenetics did not (or anecdotally) develop invasive aspergillosis, suggesting that rapid and more effective disease control of leukemia is a determining factor in the incidence and outcome of invasive fungal infections …”

Section: Discussionmentioning

confidence: 99%

“…Median EFS, RFS and OS were 7 (IQR, 3-16), 8 (4-28), and 11 (5-29) months, respectively ( Figure 1). OS was 21% [95%CI: [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] and 17% [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] at 3 and 5 years, respectively. In allografted patients, median OS starting from allogeneic stem cell transplantation was 15 months (5-NR) whereas 3-year and 5-year OS were 50% [95%CI: .…”

Section: Outcome Of Patients Treated By Intensive Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience

et al. 2019

View full text Add to dashboard Cite

A recent phase 3 trial showed that outcome of older patients with secondary acute myeloid leukemia ( AML ) may be improved by a liposomal encapsulation of cytarabine and daunorubicin ( CPX ‐351). This phase 3 study represents a unique example of prospective data in this rare subgroup providing basis for comparison with real life data. Here, we retrospectively assessed characteristics and outcome of patients aged 60‐75 years with secondary or therapy‐related AML in real life. Out of 218 patients that fulfilled CPX ‐351 study criteria, 181 patients (83.0%) received antileukemic treatment either intensive chemotherapy (n = 121) or hypomethylating agents ( HMA , n = 60). As compared with patients treated by chemotherapy, HMA ‐treated patients were older, had lower WBC , more often AML with antecedent myelodysplastic syndrome and adverse cytogenetic risk. In chemotherapy‐treated patients, the complete response rate was 69%, median overall survival ( OS ) was 11 months whereas 3‐year and 5‐year OS was 21% and 17%, respectively. In HMA ‐treated patients, the complete response rate was 15%, median OS was 11 months whereas 3‐year and 5‐year OS was 15% and 2%, respectively. In conclusion, although outcome of older patients with high‐risk AML is very poor, a significant proportion of patients treated by standard intensive chemotherapy but not HMA are long‐term survivors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Outcome Of Patients Treated By Intensive Chemotherapymentioning

confidence: 99%

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience

et al. 2019

View full text Add to dashboard Cite

show abstract

“…There have been many reports of increases in IA due to construction work (1)(2)(3)(4)(5). It has also been reported that the incidence of IA is reduced to one-sixth when patients are managed with HEPA filtration after hematopoietic stem-cell transplantation (8,9).…”

Section: Discussionmentioning

confidence: 99%

Itraconazole Prophylaxis For An Outbreak Of Invasive Aspergillosis In A Hematology Ward After Hospital Construction Work

Hirayama¹,

Terui²,

Kamihara³

et al. 2015

JHOR

View full text Add to dashboard Cite

Objective Hospital construction work, among other environmental factors, is a risk factor for invasive aspergillosis (IA). MethodsWe retrospectively surveyed the incidence of IA in hematology-oncology patients before and during hospital construction and studied the effectiveness of prophylactic oral itraconazole (ITCZ) treatment.We compared the rates of galactomannan (GM)-positive cases and probable IA cases among 224 patients discharged before the start of construction work and among 67 patients hospitalized within two months after the start of the construction work. ResultsOur results showed that, during the 12 months before the construction work was started, only four patients were GM-positive, and one had a probable diagnosis; in contrast, among patients hospitalized within two months from the start of the construction work, seven patients were GM-positive, and four had a probable diagnosis. Therefore, we started to administer oral ITCZ to 40 patients with hematological diseases.Although the construction work continued, after the ITCZ prophylaxis, no new probable cases of IA were detected.Conclusion From our experience, GM surveillance among hematological patients is necessary during hospital construction work, and the administration of ITCZ to prophylactically prevent IA is suggested upon detection of an increase in GM-positive patients .

show abstract

“…The clinical efficacy of voriconazole against the majority of fungal pathogens [Chabrol et al 2010;Gergis et al 2010;Martin et al 2010;Torres et al 2010;Trifilio et al 2007] makes it potentially very useful for the prevention of IFIs in patients with hematologic malignancies. However, given that, at present, voriconazole is widely recommended as first-line treatment for proven or probable IA [Cordonnier et al 2010;Cornely et al 2008;El-Cheikh et al 2010], this may result in strategic and therapeutic dilemmas if used as prophylaxis and in an increased risk of selection of resistant species.…”

Section: The Rationale For Voriconale As Antifungal Prophylaxismentioning

confidence: 99%

Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective review

Zabalza

Gorosquieta

Equiza

et al. 2013

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Invasive fungal infections (IFIs) have become high prevalence in patients with hematologic malignancies. Drug-based strategies for IFIs include various approaches such as prophylactic, empiric, preemptive, and directed treatment. Prophylaxis is an attractive strategy in high-risk patients, given the lack of reliable diagnostics and the high mortality rate associated with IFIs. Prophylaxis includes the use of antifungal drugs in all patients at risk. An ideal antifungal compound for prophylaxis should have a potent and broad activity, be available both orally and intravenously, and have a low toxicity profile. Voriconazole fulfills all these criteria. The clinical efficacy of voriconazole against the majority of fungal pathogens makes it potentially very useful for the prevention of IFIs in patients with hematologic malignancies. Voriconazole appears to be very effective for the primary and secondary prevention of IFIs in these patients and recipients of allogeneic hematopoietic stem-cell transplantation. Randomized controlled trials evaluating voriconazole as primary antifungal prophylaxis in patients with neutropenia treated for a variety of hematologic malignancies have been performed, confirming its value as a prophylactic agent. Voriconazole is generally safe and well tolerated; however, its use is also associated with a number of concerns. In most patients with hematologic malignancies there is the potential for pharmacokinetic drug-drug interactions given that voriconazole is metabolized through the P450 cytochrome system.

show abstract

Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia

Cited by 36 publications

References 23 publications

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience

Itraconazole Prophylaxis For An Outbreak Of Invasive Aspergillosis In A Hematology Ward After Hospital Construction Work

Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective review

Contact Info

Product

Resources

About